[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Annovis Bio Inc (ANVS)

Annovis Bio Inc (ANVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 72,004
  • Shares Outstanding, K 42,606
  • Annual Sales, $ 0 K
  • Annual Income, $ -28,850 K
  • EBIT $ -50 M
  • EBITDA $ -50 M
  • 60-Month Beta 1.24
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 272.00% (-141.42%)
  • Historical Volatility 49.78%
  • IV Percentile 56%
  • IV Rank 26.82%
  • IV High 959.05% on 04/10/26
  • IV Low 20.18% on 01/06/26
  • Expected Move (DTE 2) 0.4080 (24.14%)
  • Put/Call Vol Ratio 4.08
  • Today's Volume 2,293
  • Volume Avg (30-Day) 2,184
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 45,795
  • Open Int (30-Day) 40,702
  • Expected Range 1.2820 to 2.0980

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.30
  • Number of Estimates 1
  • High Estimate $-0.30
  • Low Estimate $-0.30
  • Prior Year $-0.37
  • Growth Rate Est. (year over year) +18.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6700 +1.20%
on 09/01/26
1.9760 -14.47%
on 08/05/26
-0.0600 (-3.43%)
since 07/31/26
3-Month
1.5500 +9.03%
on 07/28/26
2.1700 -22.12%
on 07/08/26
-0.1700 (-9.14%)
since 06/02/26
52-Week
1.5407 +9.69%
on 04/10/26
5.5000 -69.27%
on 11/28/25
-0.6400 (-27.47%)
since 09/02/25

Most Recent Stories

More News
Annovis to Host Corporate Update Webinar on September 2, 2026

MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 1.6900 (unch)
Public Healthcare Companies Meet Institutional Investors at the 5th Annual ROTH Healthcare Opportunities Conference

Public Healthcare Companies Meet Institutional Investors at the 5th Annual ROTH Healthcare Opportunities Conference

CING : 5.11 (unch)
SER : 2.50 (+3.31%)
GANX : 1.8000 (+1.69%)
BIOA : 9.52 (+0.21%)
OSTX : 1.6838 (+1.43%)
VTVT : 31.95 (-0.16%)
MASS : 10.65 (-0.19%)
PYPD : 5.33 (+3.70%)
TKNO : 7.08 (-1.39%)
OVID : 2.71 (-1.81%)
MDCX : 0.2515 (+0.12%)
EQ : 2.20 (-2.86%)
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

Pivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections. Parkinson’s disease (PD) open-label extension (OLE) study has...

ANVS : 1.6900 (unch)
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

MALVERN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 1.6900 (unch)
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease

Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028 Company positions...

ANVS : 1.6900 (unch)
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology...

ANVS : 1.6900 (unch)
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 1.6900 (unch)
Annovis Bio Regains NYSE Listing Compliance

MALVERN, Pa., May 26, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 1.6900 (unch)
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

MALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology...

ANVS : 1.6900 (unch)
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

MALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 1.6900 (unch)

Business Summary

Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.

See More

Key Turning Points

3rd Resistance Point 1.7833
2nd Resistance Point 1.7567
1st Resistance Point 1.7233
Last Price 1.6900
1st Support Level 1.6633
2nd Support Level 1.6367
3rd Support Level 1.6033

See More

52-Week High 5.5000
Fibonacci 61.8% 3.9875
Fibonacci 50% 3.5203
Fibonacci 38.2% 3.0532
Last Price 1.6900
52-Week Low 1.5407

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.